



Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan, Zhongzheng Zhu, Wei Mao, Hui Wang, Hong Qian, Jianguo Wu, Xianling Guo* and Qing Xu*

OPEN ACCESS

Edited and reviewed by:

Catherine Sautes-Fridman,
INSERM U1138 Centre de Recherche
des Cordeliers (CRC), France

*Correspondence:

Xianling Guo
yiyibaba18@163.com
Qing Xu
xuqingmd@allyun.com

Specialty section:

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Oncology

Received: 17 October 2021

Accepted: 06 December 2021

Published: 04 January 2022

Citation:

Yuan M, Zhu Z, Mao W, Wang H,
Qian H, Wu J, Guo X and Xu Q (2022)
Corrigendum: Anlotinib Combined
With Anti-PD-1 Antibodies Therapy in
Patients With Advanced Refractory
Solid Tumors: A Single-Center,
Observational, Prospective Study.
Front. Oncol. 11:796625.
doi: 10.3389/fonc.2021.796625

Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China

Keywords: anlotinib, anti-PD-1 antibody, angiogenesis, immunotherapy, serum cytokine

A Corrigendum on:

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

By Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X and Xu Q (2021). *Frontiers in Oncology* 11, doi: 10.3389/fonc.2021.683502.

In the original article, there was an error. The median PFS was incorrectly written as 8.37 months (95% CI: 6.5-10.0 months) in the abstract.

A correction has been made to Abstract, Results, Paragraph 1:
The median PFS was 4.77 months (95% CI: 4.10-5.44 months).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yuan, Zhu, Mao, Wang, Qian, Wu, Guo and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.